Diagnostic value of multiple tumor-associated autoantibodies in lung cancer

Background: Lung cancer is the leading cause of cancer-related deaths. Survival rate improves significantly with early detection of lung cancer. Effective methods of early detection can reduce lung cancer mortality to a large extent as well as benefit the whole public health. The diagnostic value of one single marker is relatively low. Combined autoantibodies (AABs) can improve the sensitivity significantly rather than rely on one AAB and serve as good reservoir for early detection of lung cancer. Patients and methods: We designed three parts in our experiment. In training set we measured the expression levels of AABs in 100 non-small-cell lung cancer (NSCLC) patients and 60 healthy controls by using ELISA detection method. A blinded validation was subsequently performed in 254 NSCLC patients, 125 healthy controls, and 71 nodule patients. A prospective expansion set was performed to evaluate the diagnosis value of AABs combined detection. Results: Both in training set and validation set, the concentrations of SOX2, GAGE 7, MAGE A1, and P53 in NSCLC group increased prominently when compared to the healthy group (P<0.05). The concentration of GBU4-5 in adenocarcinoma group was higher than in the squamous cell carcinoma (SCC) group (P<0.05); the PGP9.5, which was opposite, in SCC group was higher than in the adenocarcinoma group (P<0.05). The positive rate of each AAB did not show any bias with age, gender, smoking history, and tumor location. Most importantly, different choice of biomarkers led to different detection results. Conclusion: Our study confirmed the diagnostic value of tumor-associated AABs. They may he useful as latent tumor markers to facilitate the detection of early lung cancer.